Tissue inhibitor of metalloproteinase-3 expression affects clinicopathological features and prognosis of aflatoxin B1-related hepatocellular carcinoma

doi:10.4254/wjh.v16.i8.1131

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2011)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-8) series.

Item

Count

PDF

HTML

1102

Figures (1-1)

262

Tables (1-8)

232

Sum=1646

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

260

Sum=312

Aug 27, 2024 (publication date) through Apr 13, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Hepatol. Aug 27, 2024; 16(8): 1131-1144
Published online Aug 27, 2024. doi: 10.4254/wjh.v16.i8.1131

Table 8 Correlation between aflatoxin B1 exposure and tissue inhibitor of metalloproteinase-3 expression in hepatocellular carcinoma

	Low AFB1 exposure		High AFB1 exposure		r	P value
	n	Percentage (%)	n	Percentage (%)	r	P value
LTE	27	36.0	62	57.9	-0.216	0.003
HTE	48	64.0	45	42.1

AFB1: Aflatoxin B1; LTE: Low TIMP3 expression; HTE: High TIMP3 expression.

Citation: Liang QJ, Long QQ, Tian FQ, Su QY, Zhu XY, Long XD. Tissue inhibitor of metalloproteinase-3 expression affects clinicopathological features and prognosis of aflatoxin B1-related hepatocellular carcinoma. World J Hepatol 2024; 16(8): 1131-1144
URL: https://www.wjgnet.com/1948-5182/full/v16/i8/1131.htm
DOI: https://dx.doi.org/10.4254/wjh.v16.i8.1131